Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.130
-0.050 (-1.57%)
At close: May 13, 2026, 4:00 PM EDT
3.050
-0.080 (-2.56%)
After-hours: May 13, 2026, 7:42 PM EDT
Cyclerion Therapeutics Employees
Cyclerion Therapeutics had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
1
Change
n/a
Growth
n/a
Revenue / Employee
$1,993,000
Profits / Employee
-$5,276,000
Market Cap
13.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - |
| Sep 30, 2025 | 1 | 0 | - |
| Jun 30, 2025 | 1 | 0 | - |
| Mar 31, 2025 | 1 | 0 | - |
| Dec 31, 2024 | 1 | 0 | - |
| Sep 30, 2024 | 1 | 0 | - |
| Jun 30, 2024 | 1 | - | - |
| Mar 31, 2024 | 1 | -15 | -93.75% |
| Dec 31, 2023 | 1 | -15 | -93.75% |
| Dec 31, 2022 | 16 | -16 | -50.00% |
| Dec 31, 2021 | 32 | -2 | -5.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioLineRx | 24 |
| Moleculin Biotech | 17 |
| Genenta Science | 9 |
| Intensity Therapeutics | 7 |
| Ernexa Therapeutics | 7 |
| Lexaria Bioscience | 7 |
| Phio Pharmaceuticals | 6 |
| Hoth Therapeutics | 3 |
CYCN News
- 6 weeks ago - Why is Cyclerion Therapeutics Stock (CYCN) Up Over 160% Today? - TipRanks
- 6 weeks ago - Cyclerion Therapeutics, Korsana Biosciences enter merger agreement - TheFly
- 6 weeks ago - Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire
- 3 months ago - Cyclerion receives positive written feedback, responses on CYC-126 study - TheFly
- 3 months ago - Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board - GlobeNewsWire
- 4 months ago - Cyclerion Therapeutics enters exclusive collaboration with Medsteer - TheFly
- 4 months ago - Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewsWire
- 8 months ago - Cyclerion enters licensing agreement with MIT, announces strategic relaunch - TheFly